Meta-Analysis of the Effect of Thiazolidinediones on Serum C-Reactive Protein Levels

This publication has 19 references indexed in Scilit:

• Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: Results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study
  Clinical Therapeutics, 2005
• Estimating the mean and variance from the median, range, and the size of a sample
  BMC Medical Research Methodology, 2005
• Enhancement of insulin‐stimulated myocardial glucose uptake in patients with Type 2 diabetes treated with rosiglitazone
  Diabetic Medicine, 2004
• Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
  Diabetes Care, 2004
• Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes
  Diabetes Care, 2004
• Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
  Stroke, 2003
• A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis
  The American Journal of Cardiology, 2002
• Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
  Circulation, 2002
• Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes
  Metabolism, 2001
• Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
  Controlled Clinical Trials, 1996